About
Global execution, mid-market economics. Detroit and New York operating base. Transatlantic and transpacific deal capability.
Ambrosia Ventures is a life sciences strategic advisory and M&A firm — operating from Detroit and New York, executing transactions across North America, Europe, the Middle East, and Asia. We lead client conversations with deal intelligence, market knowledge, and structuring expertise — not relationship facilitation.
The advisory market has two crowded ends. At one end, introducers and finders work on commission-only economics — adding little structural value. At the other, bulge-bracket banks treat mid-sized and cross-border transactions as small accounts inside large coverage teams. We operate in the middle.
Senior attention throughout. Cross-border execution capability where boutiques can’t operate and bulge brackets won’t engage. Deal intelligence and structuring depth that lets us run conversations on the same footing as the principals.
Global Practice
North America
Boston, San Francisco, NYC, San Diego, RTP. Canadian academic spinout work.
Transatlantic
US ↔ EU, UK, Israel. European biotech out-licensing into US pharma. Israeli platform asset transactions.
Transpacific
US ↔ China, Korea, Japan. China-to-West licensing wave. Korean platform deal acceleration.
Specialty Cross-Border
Regulatory, IP, cultural translation complexity that boutiques can’t deliver and bulge brackets won’t pursue.
Client Segments
Clinical-stage life sciences companies preparing for or actively running a transaction process.
Emerging LS fund managers, family offices, and corporate venture arms.
Sell-side platforms positioned for acquisition. Mid-pharma buy-side clients facing patent cliffs.
We’ll meet you at peer level — anywhere in the world.